Company / Operating Cash Flow
Jazz Pharmaceuticals Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.4B
FY2025
5-year range
$776.4M / $1.4B
FY2021-FY2025
Trend
-2.9%
vs FY2024
Sector context
#20 of 216
Health Care
What the data says
Among 216 Health Care companies, Jazz Pharmaceuticals is in the top 9% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $408M in FY2016 to $1.4B in FY2024.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of +11.2%. Top quartile in the Health Care sector.
Improved from $1.1B to $1.4B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +14.6%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 216This company $1.4B Sector average $659.0M
▼
+105.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2025, operating cash flow decreased 2.9% year-over-year.
- Ranks #20 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | -2.9% |
| FY2024 | $1.4B | +27.8% |
| FY2023 | $1.1B | +21.4% |
| FY2022 | $899.6M | +15.9% |
| FY2021 | $776.4M | -2.8% |
| FY2020 | $798.9M | +15.3% |
| FY2019 | $693.1M | +17.0% |
| FY2018 | $592.4M | -14.5% |
| FY2017 | $693.1M | +70.0% |
| FY2016 | $407.6M | -23.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026